Omnicell, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023; unaudited. Omnicell sells medication-management automation, software, consumables, and services to healthcare providers and pharmacies. It reports as one operating segment.
Financial performance and position
Amounts in millions, except per-share data and percentages.
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $299.0 | $331.4 | $589.6 | $650.2 |
| Gross profit / margin | $134.4 / 45% | $158.1 / 48% | $259.5 / 44% | $308.1 / 47% |
| Operating income (loss) | $7.7 | $12.5 | $(15.2) | $17.6 |
| Net income (loss) | $3.5 | $9.1 | $(11.5) | $17.3 |
| Diluted EPS | $0.08 | $0.20 | $(0.26) | $0.37 |
| Operating cash flow | — | $85.7 | $(25.5) |
- Q2 revenue fell 10% year over year; product revenue declined 19% to $188.4 million, while services and other revenue grew 13% to $110.5 million.
- For the first half, revenue declined 9% year over year. Product revenue was down 19%; services and other revenue rose 13%.
- Six-month investing cash outflow was $28.5 million, mainly property/equipment purchases of $21.8 million and external-use software development of $6.7 million. Financing provided $7.5 million. Cash, cash equivalents, and restricted cash increased $64.8 million.
- At June 30, cash and cash equivalents were $399.5 million; working capital was $511.2 million and the current ratio was 2.4:1. Including restricted cash, cash and restricted cash totaled $417.7 million.
- Debt included $575 million principal of 0.25% convertible notes due September 2025, reported net at $568.1 million. No revolver borrowings were outstanding; $417.7 million was available under the facility. The company reported compliance with credit agreement covenants.
Changes versus the prior comparable period
- Lower automated-dispensing-system revenue, which management attributed primarily to health-system capital-budget and labor constraints, drove the product revenue decline. Services growth reflected Advanced Services demand, installed-base growth, and pricing actions.
- Gross margin declined 3 percentage points in Q2 and 3 points for the first half. Management cited weaker product revenue and fixed labor and overhead costs that did not fall proportionally; lower inventory-related costs partly offset the pressure.
- Operating expenses decreased 13% in Q2 and 5% for the first half, including lower employee-related, consulting, and commission expenses. Six-month operating results nevertheless moved from income to loss.
- First-half operating cash flow improved from an outflow in 2022, aided by collections and lower inventory, as well as increased deferred revenue. Working-capital movements materially affected cash flow in both periods.
Outlook, risks, and unusual items
- The filing provides no quantitative revenue or earnings guidance. Management said existing cash, expected operating cash flows, employee equity-plan proceeds, and revolver availability should cover working capital, capital expenditures, potential acquisitions, and contractual obligations for at least the next 12 months.
- Management identified customer capital budgets and approval cycles, installation timing and capacity, product supply and quality, and foreign-exchange movements as factors affecting results. It described ongoing macroeconomic headwinds and expense-containment actions.
- Restructuring actions included workforce reductions and a smaller real-estate footprint. First-half 2023 employee-related restructuring expense was $6.0 million; cumulative employee severance-related expense under the plan was $23.5 million. The company also recorded $7.8 million of lease right-of-use asset impairment and abandonment charges during the first half.
- No material ransomware-related expenses were incurred in the first half of 2023. Since the May 2022 incident, cumulative expenses were $13.6 million, partly offset by $11.1 million of insurance recoveries; $10.9 million had been received by June 30, 2023.
- A biometric-privacy class action was settled for $4.3 million; final payment was made in April 2023 and claims were dismissed with prejudice. The company reported no material accrual for other current legal proceedings, while noting litigation outcomes are uncertain.
- Deferred revenue totaled $173.4 million at June 30, 2023. Reported remaining performance obligations not included in deferred revenue were $288.7 million. Separately, the company disclosed that $87.6 million had been inadvertently omitted from the RPO previously reported at March 31; including it would have brought that prior-period balance to $286.8 million.
- Disclosure controls were assessed as effective at the reasonable-assurance level; the filing reported no material changes in internal control over financial reporting during the quarter. No material changes to previously disclosed risk factors were reported.
Key facts for investors to verify
- Whether product demand and installation timing recover, and whether service growth can offset continued weakness in equipment sales.
- The drivers and persistence of gross-margin pressure, including the effect of fixed manufacturing costs and restructuring.
- The quality and timing of cash generation, including reliance on working-capital movements and the composition of restricted cash.
- The RPO omission and correction: confirm the reported $288.7 million June 30 balance and understand the scope and timing of the prior-period adjustment.
- Liquidity and refinancing considerations for the $575 million convertible notes due in 2025, plus credit-facility availability and covenant headroom.